Printer Friendly

The heart-placenta axis in the first month of pregnancy: induction and prevention of cardiovascular birth defects.

1. Environmental Influences

Extrapolation of experimental results using mouse and avian embryonic models demonstrates that environmental factors present in utero during the second to third week of human gestation (human, 16 to 19 days after fertilization; mouse, embryonic days ED 6.75 to 7.5; avian, HH stage 4 to stage 5-) can alter early developmental processes resulting in severe cardiac anomalies [1-5]. Some perturbations may alter development in a manner that may not be clinically evident at birth, but result in increased susceptibility to cardiac problems after birth, or increasingly as we age. In a recent study published in September 2012 [6], NIH Common Fund researchers reported on genome-wide association studies (GWASs) of genetic variants, specifically pertaining to noncoding regions of DNA that actively regulate gene expression. They found that 88 percent of GWAS variants are in regulatory DNA regions of genes that are active in fetal development, including variants associated with adult-onset disease. The finding that a large number of disease-associated variants are located in regulatory DNA regions that are active during embryonic development suggests that environmental exposures affecting the intrauterine milieu during early embryonic stages can influence risk for not only birth defects, but also a large number of adult diseases. This concept of developmental origins of health and adult disease arose with data that the intrauterine milieu influences cardiovascular and mental diseases long into adulthood [7-9].

Early in human gestation following conception, the fertilized embryo implants in the uterine wall. The successful implantation requires adequate maternal uterine perfusion and endogenous hormone preparation to allow initial embryonic survival and later organ development and growth for a term gestation. Shortly after implantation, cardiomyocyte specification and commitment take place between 16-19 days postconception (pc). The circulation and a beating tubular heart are established by 21 days pc in human pregnancy. In mouse development, cardiac specification corresponds to embryonic day (E) 6.75 to E7.5 whereby the cardiac crescent forms. Next, a beating, linear, and tubular heart forms that then loops and septates (E10.5) to form a four-chambered heart (4-6 weeks of human gestation). Human cardiac morphological development is complete by 8 weeks of age.

Abnormal cardiac development leading to congenital heart disease can be associated with abnormal placental development with abnormal trophoblast invasion and remodeling and the resultant abnormal transfer of nutrients and oxygen from the mother to the fetus [10,11]. Studies relating to germ-line ablation of specific genes, as p38[alpha]-mitogen activated protein (MAP) kinase or of peroxisome proliferator-activated receptors (PPARs), demonstrated they were critical for proper placental function and, when ablated only in the placenta, resulted in cardiac defects. When the placental function was rescued via aggregation with tetraploid embryos (tetraploid morulas failed to contribute to embryonic tissues, only placental), this corrected the cardiac defect [10,11]. These studies highlight the existence of a critical heart-placental axis that is just beginning to be recognized.

The heart-placental axis is associated with parallel development of the placenta and heart that utilizes many common molecules and genes [11-16] and reflects intimate and synergistic growth of both organs. Two important pathways critical to placental development, implantation, and cardiac development during the same period of early development are canonical Wnt/[beta]-catenin signaling and pathways associated with folate metabolism [17-21]. If these pathways are altered, developmental anomalies ensue. Failure to maintain a pregnancy or have normal cardiac development may be due to abnormal placental function or cardiac function. Fetal loss can occur prior to usual detection of pregnancy at 5 to 6 weeks of gestation (estimated to be a significant percent of all fertilized embryos) or occurs later after initiation of the embryonic heartbeat. Placental volume blood flow is a major determinant of early cardiac output, fetal growth, and well-being [22,23]. The associated placental abnormality during gestation of the fetus with congenital heart disease has deleterious effects on the outcome of pregnancy. There may be such severe starvation of the fetal circulation and growth failure that growth arrest, severe hypoxemia and marginal cardiac output occur with spontaneous loss of the pregnancy. Premature delivery may result in birth of a neonate with poor prognosis related to the prematurity and low birth weight. Management of the neonate with prematurity and congenital heart disease is associated with a very high perinatal mortality.

The underlying mechanisms by which environmental exposures can result in congenital birth defects, as well as disease much later in life, have had no clear experimental definitions, but there is evidence that cellular processes associated with cell fate decisions and cell lineage modulation are involved [4, 24]. In the case of cardiomyocyte specification, it is among the earliest cell-fate decisions to occur, because the heart-cardiovascular system is the first organ-system to develop. The statistic that 49% of all pregnancies are unplanned [25], would indicate the first month is a high risk period for the early embryo and specifically for cardiovascular development, neurogenesis, and for placentation in that in all three organ systems important steps in cell specification and early differentiation processes are taking place that are regulated by the same signaling pathways, specifically as we have reported, Wnt/[beta]-catenin signaling.

The focus of my research has been on early stages of heart development, specifically regulation of cardiac cell specification and differentiation using the mouse and avian embryonic models. In the human embryo, a beating, tubular heart with extra- and intraembryonic circulations bringing blood to the heart is present at 21 days. Because cardiac cell fate decisions are taking place several days earlier, approximately at 16 to 19 days of human pregnancy, these early periods of human gestation are not possible to analyze on a cell and molecular level. Thus, the mouse model is an excellent mammalian model to analyze developmental processes leading to a functional heart. With present day technologies, both cardiac structural and functional relationships can be monitored in the mouse embryo using Doppler ultrasound (Figure 1).

Noninvasive evaluation of fetal heart function during early human pregnancy using clinical echocardiography is challenging. The earliest variables of early fetal cardio-circulatory dynamics have been established for 11-14 weeks of gestation [26]. Those critical developmental processes are already well underway in cardiogenesis by the time pregnancy is usually confirmed at weeks 5/6 after-fertilization which may relate to why congenital heart defects arise in 1% of births world-wide and of all birth defects are the most common. As the heart is the first organ-system to develop, followed closely by the nervous system, our recent research on early development using environmental exposure during gastrulation may help to explain why cardiac birth defects are so prevalent and are the leading cause of infant mortality. In the first month, women may be continuing to use prescribed medications or leisure drugs, to smoke, and to drink alcohol, may be type-2 diabetic or obese, and not be following neither healthy lifestyles or diets, nor protecting their embryos with prescribed perinatal folate supplementation.

Multiple early processes are associated with similar signaling pathways in heart, placental, and neural development, and thus development of different tissues in the same embryos can be affected with the same exposures [27]. In a recent study of infants in the Atlanta metropolitan area, 28.7% of infants with CHDs also had associated major noncardiac malformations [28]. If one reads the literature provided to women upon learning of their pregnancy usually at 5 to 6 weeks after conception, pamphlets predominantly focus on neural development and the use of folate during pregnancy with targeting the second to third month of gestation. Possibly due to a lack of knowledge on effects of environmental exposures during early embryonic development, generally there is little discussion of adverse effects on cardiac outcomes, importance of planned pregnancy, and the use of folate before becoming pregnant and continuing until pregnancy is confirmed, so as to protect the earliest stages of embryonic development, specifically of the cardiovascular system [5,18], placentation [29], and neurogenesis [30].

2. Cardiac Birth Defects

Our results with animal models demonstrate that even before pregnancy is realized, many different forms of cardiac birth defects can arise with just a single environmental exposure occurring during gastrulation. Cardiac structural and functional defects in mouse embryos we have shown can result with one-time exposure to the drug lithium, alcohol, or homocysteine, the latter a marker of folate deficiency [5,18]. We analyzed different parameters of the cardiac cycle and umbilical blood flow using ultrasound (Vevo 770, Visual-Sonics, Inc., Toronto, Ca, instrumentation) with a 40 mHz transducer or a clinical instrument (Philips Sonos 5500, Andover, MA) with a 12 mHz transducer. Both transducers demonstrated similar blood flow patterns. Maternal uterine artery blood flow velocity waveforms were obtained, and the pulsatility index was calculated. Blood flow in the heart and blood vessels was detected in each embryo using two-dimensional real-time echocardiography. Color Doppler was used to identify the embryonic heart and directed pulse Doppler to obtain blood flow velocity waveforms (Figure 1). For venous hemodynamics, we used the presence of flow reversal during atrial contraction (A wave) in the ductus venosus and the presence of umbilical venous pulsations. The abnormal echocardiographic patterns relating to myocardial and valve defects have been published [17,18]. Our research indicates that the observed cardiac defects are preventable with folate supplementation that is initiated early after conception and at higher doses than presently available in periconceptional vitamins.

3. Common Cardiac Birth Defects Arise with Acute Environmental Exposure to Lithium, Homocysteine, or Alcohol

The causes of congenital heart disease (CHD) can be many, but it is generally assumed that the majority of mutations is not in the fetal organs but in the mother resulting in an altered environment for the developing embryo that predisposes to fetal malformations [32-36]. As changes in cellular processes that relate to cell fate decisions and determination of cell lineages are thought to underlie many birth defects, it is important to have an understanding of the pathways involved during specification and early differentiation stages of the heart-placental axis. What has not been explored are the etiological or simultaneous environmental modulation of embryonic cardiac and placental functional proteins and developmental pathways. Little research has been done to assay the biomarkers of CHD at a high-risk period of cardiac development, that is, during 3-6 weeks of human gestation, since most women do not know they are pregnant until after the abnormal placental/cardiac microenvironment already has had its deleterious effect on the early stages of the developing embryo.

It has been demonstrated that normal heart function relates to formation of normal cardiac structure [37,38]. Multiple mechanotransducing structures and molecules coordinate detection of blood flow forces with morphogenesis [39-42]. In our mouse studies, we observed that even one-time environmental exposure during gastrulation (ED 6.75 to 8.0; extrapolating to human gestation, 16-19 days postconception) is associated with abnormal umbilical artery blood flow, lower weight fetuses, and both structural and functional cardiac anomalies [4, 5,18]. Although the mammalian embryo is well protected in the uterus, environmental chemicals, drugs, and maternal nutritional imbalances can interfere with signaling pathways directing placental and embryonic development early in gestation. These environmental factors are thought now to cause at least 7% to 10% of all congenital anomalies [43]. Because biochemical differentiation precedes morphological outcome often by days (Figure 2), the period of susceptibility to environmental chemicals expectedly precedes visible morphogenic effects.

In our studies, we have focused on embryonic exposure to the drug lithium (Li) widely used for bipolar disorder, the metabolic intermediary homocysteine (HCy) in the folate pathway, or alcohol (ethanol; EtOH). With the same timing of acute exposure, all three induce similar gene misexpression of Wnt-mediated genes Hex and Islet-1 in the cardiogenic crescent during specification. Subsequently, all exposures result in heart, valve, and placental abnormalities [4, 24]. The exposure effects appear to intersect with an early, critical signaling pathway, the canonical Wnt/[beta]-catenin pathway, important in the prechordal plate, in cardiac induction, valve development [24, 44-47], and in placentation [48, 49] and neurogenesis [50-52]. Alterations that occur in the placenta and in the heart fields in response to acute exposure of mouse embryos on ED 6.0 at 6 PM, that is, ED 6.75, to Li, alcohol, or elevated homocysteine levels that correlate with changes ~ a week later on ED15.5 in umbilical blood flow, abnormal heart (myocardial) function and formation, and valve anomalies in 63.2%, 86.6%, and 66.1% of the embryos, respectively [4, 5, 18]. In comparison to control embryos demonstrating normal cardiac development, there was a high incidence of semilunar valve abnormalities with our timing of the acute exposure. The one-time exposure at E6.75 corresponds to embryonic gastrulation, when the embryo is comprised of only the three germ layers (Figure 2(a)), the ectoderm, mesoderm, and endoderm. This is a time-period during which the primary and second heart fields are being specified (Figures 2(b)-2(d)) in the bilateral anterior mesoderm regions of the embryo [31, 53-57]. Both Hex expression, an important inducer of primary heart field specification and Islet-1, a marker of the second heart field that leads to the development of the outflow [58, 59], were suppressed with the acute environmental exposure [5, 18]. The delay in regulatory gene expression led to a delay in the migration of cardiac precursors to the embryonic midline resulting in a lethal condition known as cardiabifida and/or to abnormal differentiation of part of the heart wall [4]. Dependent on length of exposure and the dose, variability in heart development is seen in regards to degree of cardia-bifida and the part of the myocardium that is affected (see Figure 3). Effects of exposure could lead to early embryonic demise, to cardiac anomalies relating to the induction of valves or the conduction system, or to eventual myocardial disease as adults.

Defects in cardiac valves are the most common subtype of cardiac defects, and account for 25%-30% of all cardiovascular malformations [60]. Our published results on lithium exposure administered during gastrulation suggested an additional possible basis for the high incidence of valve defects with early embryonic exposure. We made the observation that early cell populations extrinsic to the heart fields arising during gastrulation, specifically the prechordal plate cells [61-64], were susceptible to environmental lithium exposure and failed to contribute in normal numbers to a cell population that localizes to the ventral floor of the foregut and that contributes to the dorsal mesenchymal protrusion (DMP) region [65]. Kirby et al. showed that these cells eventually move into the endocardium [61]. Our lithium exposure studies suggested that this cell population within the DMP arises initially in the prechordal plate, and after migration into the endocardium may become associated with endocardial cushions contributing to valvulogenesis. If the prechordal plate cells are inhibited in their migration as they are by lithium exposure, then cells in the Wnt-expressing valve regions are much more sparse than seen in control embryos and abnormal valvular function was observed in the experimental embryos [4]. Gastrulation is an earlier period of development than generally has been considered to relate to valve abnormalities, although there is evidence from pathological analysis that early cell populations are contributing to valves [65-67]. Valve structural morphogenesis itself takes place much later, that is, after a tubular heart has formed [68, 69].

4. Environmental Effects on the Placenta

This same time period of embryonic exposure during gastrulation also relates to the formation of the placenta [15, 16, 70]. We recently published that exposure to lithium, homocysteine, or alcohol modulate gene and protein expression in human HTR-8/SVneo extravillous trophoblasts in culture and in vivo in the mouse placentas of the same embryos that demonstrated cardiac anomalies [71]. Central to the placenta's function is its vascular labyrinth, a parallel series of finely branched blood vessels and trophoblasts that regulate nutrient, gas, and waste exchange while keeping the maternal-fetal blood supplies separate. After implantation, angiogenic-vasculogenic processes promote formation of the highly arborized labyrinth vascular bed [72]. In addition to the role of trophoblasts in spiral artery remodeling, migration of trophoblasts in response to chemokines [73] is important in the colonization of the maternal decidua [74] between ED 7.5-10.5 of gestation [75]. The Wnt antagonist Dickkopf-l's modulation of Wnt/[beta]-catenin signaling plays a critical role in regulating the equilibrium between active and inactive Wnt signaling in the utero-placental interaction [76, 77]. Although human placentation differs from that of the rodent model, there is homology regarding trophoblast invasion and in the important regulatory elements [78]. We found that alcohol exposure as well as lithium and homocysteine did not affect cell proliferation, but rather trophoblast cell migration [17]. All three environmental exposures modulated placental nonmuscle-myosin-heavy-chain-(NMHC-) IIA and NMHC-IIB expression (Figure 4). NMHC-IIA has been reported to have a unique role in the placenta and when deleted embryonic lethality ensued [79]. NMHC-IIB, a protein associated with cell motility, also has a role in heart looping and trabeculation [39, 80, 81].

5. Folate Protection of Normal Heart-Placental Axis Formation and Prevention of Birth Defects

There is a general acceptance that folate aids in the prevention of neural tube defects. There is an increasing evidence, including our own, that folate supplementation can prevent or reduce the risk and severity of congenital heart disease induced by an abnormal uterine microenvironment. Prenatal treatment with folate has been shown to prevent neural tube defects and reduce the severity of CHD in clinical studies [82-88]. In animal analyses using chick and mouse models, supplementation of folate or simultaneous supplementation of folate and myo-inositol have been shown to prevent the teratogenic effects of a number of environmental molecules that can affect human gestation, including alcohol [5,18]. In human epidemiological studies, folate doses of 10 mg/kg have proven effective in preventing cardiovascular defects [87]. In our mouse studies, a metabolic weight dose equivalent of 10.5 mg/kg maternal weight completely prevented cardiac defects induced during gastrulation [5, 18], but a more moderate dose of 6.2 mg/kg provided only partial protection. No deleterious effects on normal development were noted with these doses. These results suggest that a slightly higher dose of folate may be necessary for the prevention of cardiac birth defects than for neural tube defects where 1 mg/kg FA maybe given for high riskpregnancies. A mouse study using a folate dose 4 times higher than ours, that is, 40 mg/kg, showed that such a high dose was deleterious to normal embryonic development [89]. It appears that these investigators were using a dose within a toxic range. It is suggested that more clinical studies are needed to define an optimal FA dose for the prevention of CHD in human pregnancy.

The folate pathway not only relates to purine and pyrimidine synthesis important in DNA synthesis and cell proliferation, but also to the synthesis of the primary methyl donor S-adenosylmethionine (SAM) important in methylation reactions of cellular lipids, proteins, RNA, and DNA. DNA methylation is critical to epigenetic regulation of gene expression [90-92]. Epigenetic factors that predispose to congenital heart disease, and placental dysfunction are suspected to be the cause of an increase in the recurrence risk of CHD after one affected child. During cell differentiation, gene expression patterns are controlled through two principle mechanisms. The best understood is imposed through the DNA sequence itself. The second or "epigenetic" relates to heritable changes in gene function that occur independently of alterations in primary DNA sequence. The best-characterized epigenetic modifications are DNA methylation and histone modifications, both of which function in Wnt signaling, a critical pathway in early cardiomyogenesis [24, 44, 45, 47, 93], neurogenesis [50, 94-96], and placentation [48]. Vertebrate DNA methylation is in general restricted to cytosine (C) nucleotides in the sequence CG, known as CpG islands. DNA methyltransferases (Dnmts) are the enzymes responsible for DNA methylation. A principle source of methyl groups in the cell is S-adenosyl methionine (SAM) synthesized by the FA metabolic cycle. In the early embryo, DNA after fertilization undergoes progressive demethylation and becomes hypomethylated during the pluripotential stages [97]. As cells differentiate, a more hypermethylated state is attained, as cells "lock-in" their own specific fate and other genes are silenced through methylation [98]. Thus, specificity of DNA methylation patterns is expected for specific cell types. However, recent evidence indicates that neither all genes are methylated with differentiation nor all genes that are methylated are necessarily silenced. Epigenetics are important areas for analysis in relation to birth defects.

Canonical Wnt signaling is necessary for the induction of cardiogenesis [44] to occur, but if potentiated or prolonged beyond when it is normally downregulated in the heart fields by Wnt antagonists such as Dkk-1 and by Wnt 11, it becomes inhibitory to differentiation [24,47, 99]. In the human DKK1 gene expression involves regulation by DNA methylation within its promoter [100]. Recent reports demonstrated that alcohol exposure altered DNA methylation profiles in mouse embryos at early neurulation [101] and the patterning of 5-methylcytosine expression during neurogenesis [102]. Another study reported on a correlation between chronic alcohol use, for example, and demethylation of normally hypermethylated imprinted regions in sperm DNA [103]. Thus, as based on our studies and that of others, analyses of one-carbon metabolism and specific epigenetic effects of embryonic environmental exposure in the induction of placental and cardiac anomalies and of folate in the prevention of abnormal development are warranted. Given that a high percentage of pregnancies are unintended, the mechanism of action of the folate and intersecting pathways during early gestation together with prophylactic mechanisms involving epigenetic effects are critical to define in the placenta-heart axis.

There is an increasing awareness in the last 4 to 5 years that increased levels of attention are necessary to be brought to environmental exposures occurring in the first month of pregnancy in the etiology of congenital heart defects [104]. Epidemiological studies and statistics provide the basis for the necessity to study early embryonic development in relation to the uterine environment and the formation of birth defects. 120,000 to 160,000 children are born with major birth defects each year (3%-5% of all live births). Twelve percent of admissions to pediatric hospitals relate to children with birth defects [105]. Not withstanding the stress and toll of birth defects to the child and family, fifteen of the most significant birth defects have a cost to society of $8 billion annually. Genetic mutations and chromosomal abnormalities account for approximately 28% of birth defects among affected individuals [106]. More than 66% of birth defects, however, relate to unknown, most likely multifactorial causes, including environmental influences. Understanding how and when in utero environmental exposures affect embryonic gene regulation and which pathways are perturbed will provide insights into ways to prevent disease and birth defects by reducing effects of exposures early in life, instead of treating the anomaly often by surgery or the disease when symptoms occur in adulthood.

http://dx.doi.org/10.1155/2013/320413

References

[1] B. A. Bailey and R. J. Sokol, "Pregnancy and alcohol use: evidence and recommendations for prenatal care," Clinical Obstetrics and Gynecology, vol. 51, no. 2, pp. 436-444, 2008.

[2] H. J. Bruyere Jr. and C. E. Stith, "Strain-dependent effect of ethanol on ventricular septal defect frequency in White Leghorn chick embryos," Teratology, vol. 48, no. 4, pp. 299-303, 1993.

[3] S. M. Smith, "The avian embryo in fetal alcohol research," Methods in Molecular Biology, vol. 447, pp. 75-84, 2008.

[4] J. Chen, M. Han, S. M. Manisastry et al., "Molecular effects of lithium exposure during mouse and chick gastrulation and subsequent valve dysmorphogenesis," Birth Defects Research A, vol. 82, no. 7, pp. 508-518, 2008.

[5] M. Serrano, M. Han, P. Brinez, and K. K. Linask, "Fetal alcohol syndrome: cardiac birth defects in mice and prevention with folate," American Journal of Obstetrics and Gynecology, vol. 203, no. 1, pp. 75.e7-75.e15, 2010.

[6] M. T. Maurano, R. Humbert, E. Rynes et al., "Systematic localization of common disease-associated variation in regulatory DNA," Science, vol. 337, pp. 1190-1195, 2012.

[7] D. J. P. Barker, "The origins of the developmental originstheory," Journal of Internal Medicine, vol. 261, no. 5, pp. 412-417, 2007

[8] D. Barker, "Human growth and cardiovascular disease," Nestle Nutrition Workshop Series, vol. 61, pp. 21-33, 2008.

[9] D. J. Barker, R. L. Bergmann, and P. L. Ogra, "Concluding remarks. The window of opportunity: pre-pregnancy to 24 months of age," Nestle Nutrition Workshop Series, vol. 61, pp. 255-260, 2008.

[10] R. H. Adams, A. Porras, G. Alonso et al., "Essential role of p38a MAP kinase in placental but not embryonic cardiovascular development," Molecular Cell, vol. 6, no. 1, pp. 109-116, 2000.

[11] Y. Barak, M. C. Nelson, E. S. Ong et al., "PPARy is required for placental, cardiac, and adipose tissue development," Molecular Cell, vol. 4, no. 4, pp. 585-595, 1999.

[12] J. C. Cross and L. Mickelson, "Nutritional influences on implantation and placental development," Nutrition Reviews, vol. 64, no. 5, pp. S12-S18, 2006.

[13] M. Hemberger and J. C. Cross, "Genes governing placental development," Trends in Endocrinology and Metabolism, vol. 12, no. 4, pp. 162-168, 2001.

[14] J. Clark, K. E. Anderson, V. Juvin et al., "Quantification of PtdInsP3 molecular species in cells and tissues by mass spectrometry," Nature Methods, vol. 8, no. 3, pp. 267-272, 2011.

[15] S. J. Monkley, S. J. Delaney, D. J. Pennisi, J. H. Christiansen, and B. J. Wainwright, "Targeted disruption of the Wnt2 gene results in placentation defects," Development, vol. 122, no. 11, pp. 3343-3353, 1996.

[16] S. Peng, J. Li, C. Miao et al., "Dickkopf-1 secreted by decidual cells promotes trophoblast cell invasion during murine placentation," Reproduction, vol. 135, no. 3, pp. 367-375, 2008.

[17] M. Han, A. L. Neves, M. Serrano et al., "Effects of alcohol, lithium, and homocysteine on nonmuscle myosin-II in the mouse placenta and human trophoblasts," American Journal of Obstetrics and Gynecology, vol. 207, no. 2, pp. 140.e7-140.e19, 2012.

[18] M. Han, M. C. Serrano, R. Lastra-Vicente et al., "Folate rescues lithium-, homocysteine- and Wnt3A-induced vertebrate cardiac anomalies," Disease Models and Mechanisms, vol. 2, no. 9-10, pp. 467-478, 2009.

[19] K. K. Linask and J. Huhta, "Folate protection from congenital heart defects linked with canonical Wnt signaling and epigenetics," Current Opinion in Pediatrics, vol. 22, no. 5, pp. 561-566, 2010.

[20] M. Serrano, M. Han, J. C. L. Huhta, R. Lastra, B. Garita, and K. K. Linask, "Folate suppresses Wnt/[beta]-catenin inhibition of cardiogenesis to protect against induction of congenital heart defects," in Proceedings of the American Heart Association Meeting, New Orleans, La, USA, 2008.

[21] M. C. Serrano, K. K. Linask, G. Acharya, J. Chen, M. Han, and J. C. Huhta, "One-time lithium dose in early gestation causes placental and cardiac dysfunction," American Journal of Obstetrics & Gynecology, vol. 195, no. 6, p. S210, 2007

[22] G. Acharya, T. Erkinaro, K. Makikallio, T. Lappalainen, and J. Rasanen, "Relationships among Doppler-derived umbilical artery absolute velocities, cardiac function, and placental volume blood flow and resistance in fetal sheep," American Journal of Physiology, vol. 286, no. 4, pp. H1266-H1272, 2004.

[23] G. Acharya, T. Wilsgaard, G. K. R. Berntsen, J. M. Maltau, and T. Kiserud, "Reference ranges for serial measurements of blood velocity and pulsatility index at the intra-abdominal portion, and fetal and placental ends of the umbilical artery," Ultrasound in Obstetrics and Gynecology, vol. 26, no. 2, pp. 162-169, 2005.

[24] S. M. Manisastry, M. Han, and K. K. Linask, "Early temporal-specific responses and differential sensitivity to lithium and Wnt-3A exposure during heart development," Developmental Dynamics, vol. 235, no. 8, pp. 2160-2174, 2006.

[25] D. S. Walker, C. S. Fisher, A. Sherman, B. Wybrecht, and K. Kyndely, "Fetal alcohol spectrum disorders prevention: an exploratory study of women's use of, attitudes toward, and knowledge about alcohol," Journal of the American Academy of Nurse Practitioners, vol. 17, no. 5, pp. 187-193, 2005.

[26] W. Rozmus-Warcholinska, A. Wloch, G. Acharya et al., "Reference values for variables of fetal cardiocirculatory dynamics at 11-14 weeks of gestation," Ultrasound in Obstetrics and Gynecology, vol. 35, no. 5, pp. 540-547, 2010.

[27] T. Kaukola, J. Rasanen, R. Herva, D. D. Patel, and M. Hallman, "Suboptimal neurodevelopment in very preterm infants is related to fetal cardiovascular compromise in placental insufficiency," American Journal of Obstetrics and Gynecology, vol. 193, no. 2, pp. 414-420, 2005.

[28] A. Miller, T. Riehle-Colarusso, C. J. Alverson, J. L. Frias, and A. Correa, "Congenital heart defects and major structural noncardiac anomalies, Atlanta, Georgia, 1968 to 2005," Journal of Pediatrics, vol. 159, no. 1, pp. 70-78.e2, 2011.

[29] M. Han, A. L. Neves, M. Serrano et al., "Comparison of effects of alcohol, lithium, and elevated homocysteine exposure on nonmuscle myosin IIB expression in the mouse placenta and human trophoblasts," American Journal of Obstetrics & Gynecology, vol. 207, no. 2, pp. 140.e7-140.e19.

[30] S. Giles, P. Boehm, C. Brogan, and J. Bannigan, "The effects of ethanol on CNS development in the chick embryo," Reproductive Toxicology, vol. 25, no. 2, pp. 224-230, 2008.

[31] K. K. Linask, "Regulation of heart morphology: current molecular and cellular perspectives on the coordinated emergence of cardiac form and function," Birth Defects Research C, vol. 69, no. 1, pp. 14-24, 2003.

[32] E. Goldmuntz, "The epidemiology and genetics of congenital heart disease," Clinics in Perinatology, vol. 28, no. 1, pp. 1-10, 2001.

[33] A. K. Nath, M. Krauthammer, P. Li et al., "Proteomic-based detection of a protein cluster dysregulated during cardiovascular development identifies biomarkers of congenital heart defects," PLoS ONE, vol. 4, no. 1, Article ID e4221, 2009.

[34] E. Bovill, S. Westaby, S. Reji, R. Sayeed, A. Crisp, and T. Shaw, "Induction by left ventricular overload and left ventricular failure of the human Jumonji gene (JARID2) encoding a protein that regulates transcription and reexpression of a protective fetal program," Journal of Thoracic and Cardiovascular Surgery, vol. 136, no. 3, pp. 709-716, 2008.

[35] J. Long, P. J. Lupo, E. Goldmuntz, and L. E. Mitchell, "Evaluation of heterogeneity in the association between congenital heart defects and variants of folate metabolism genes: conotruncal and left-sided cardiac defects," Birth Defects Research A, vol. 91, pp. 879-884, 2011.

[36] E. Goldmuntz, S. Woyciechowski, D. Renstrom, P. J. Lupo, and L. E. Mitchell, "Variants of folate metabolism genes and the risk of conotruncal cardiac defects," Circulation, vol. 1, no. 2, pp. 126-132, 2008.

[37] J. R. Hove, R. W. Keister, A. S. Forouhar, G. Acevedo-Bolton, S. E. Fraser, and M. Gharib, "Intracardiac fluid forces are an essential epigenetic factor for embryonic cardiogenesis," Nature, vol. 421, no. 6919, pp. 172-177, 2003.

[38] D. Sedmera, "Form follows function: developmental and physiological view on ventricular myocardial architecture," European Journal of Cardio-thoracic Surgery, vol. 28, no. 4, pp. 526-528, 2005.

[39] B. Garita, M. W. Jenkins, M. Han et al., "Blood flow dynamics of one cardiac cycle and relationship to mechanotransduction and trabeculation during heart looping," American Journal of Physiology, vol. 300, no. 3, pp. H879-H891, 2011.

[40] K. K. Linask and M. Vanauker, "A role for the cytoskeleton in heart looping," The Scientific World Journal, vol. 7, pp. 280-298, 2007.

[41] B. C. W. Groenendijk, B. P. Hierck, A. C. Gittenberger-De Groot, and R. E. Poelmann, "Development-related changes in the expression of shear stress responsive genes KLF-2, ET-1, and NOS-3 in the developing cardiovascular system of chicken embryos," Developmental Dynamics, vol. 230, no. 1, pp. 57-68, 2004.

[42] B. C. W. Groenendijk, B. P. Hierck, J. Vrolijk et al., "Changes in shear stress-related gene expression after experimentally altered venous return in the chicken embryo," Circulation Research, vol. 96, no. 12, pp. 1291-1298, 2005.

[43] K. L. Moore and T. V. N. Persaud, The Developing Human: Clinically Oriented Embryology, Saunders, Philadelphia, Pa, USA, 2003.

[44] C. Kwon, J. Arnold, E. C. Hsiao, M. M. Taketo, B. R. Conklin, and D. Srivastava, "Canonical Wnt signaling is a positive regulator of mammalian cardiac progenitors," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 26, pp. 10894-10899, 2007.

[45] C. Kwon, K. R. Cordes, and D. Srivastava, "Wnt/[beta]-catenin signaling acts at multiple developmental stages to promote mammalian cardiogenesis," Cell Cycle, vol. 7, no. 24, pp. 3815-3818, 2008.

[46] K. K. Linask, K. A. Knudsen, and Y. H. Gui, "N-Cadherincatenin interaction: necessary component of cardiac cell compartmentalization during early vertebrate heart development," Developmental Biology, vol. 185, no. 2, pp. 148-164, 1997

[47] S. Ueno, G. Weidinger, T. Osugi et al., "Biphasic role for Wnt/[beta]-catenin signaling in cardiac specification in zebrafish and embryonic stem cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 23, pp. 9685-9690, 2007.

[48] J. Pollheimer, T. Loregger, S. Sonderegger et al., "Activation of the canonical wingless/T-cell factor signaling pathway promotes invasive differentiation of human trophoblast," American Journal of Pathology, vol. 168, no. 4, pp. 1134-1147, 2006.

[49] S. Sonderegger, H. Husslein, C. Leisser, and M. Knofler, "Complex expression pattern of Wnt ligands and frizzled receptors in human placenta and its trophoblast subtypes," Placenta, vol. 28, pp. S97-S102, 2007.

[50] M. I. Garcia-Castro, C. Marcelle, and M. Bronner-Fraser, "Ectodermal Wnt function as a neural crest inducer," Science, vol. 297, no. 5582, pp. 848-851, 2002.

[51] A. K. Knecht and M. Bronner-Fraser, "Induction of the neural crest: a multigene process," Nature Reviews Genetics, vol. 3, no. 6, pp. 453-461, 2002.

[52] S. Ruffins and M. Bronner-Fraser, "A critical period for conversion of ectodermal cells to a neural crest fate," Developmental Biology, vol. 218, no. 1, pp. 13-20, 2000.

[53] K. L. Waldo, M. R. Hutson, C. C. Ward et al., "Secondary heart field contributes myocardium and smooth muscle to the arterial pole of the developing heart," Developmental Biology, vol. 281, no. 1, pp. 78-90, 2005.

[54] K. L. Waldo, D. H. Kumiski, K. T. Wallis et al., "Conotruncal myocardium arises from a secondary heart field," Development, vol. 128, no. 16, pp. 3179-3188, 2001.

[55] M. V. de la Cruz and C. Sanchez-Gomez, "Straight tube heart. Primitive cardiac cavities vs. primitive cardiac segments," in Living Morphogenesis of the Heart, M. V. de la Cruz and R. R. Markwald, Eds., pp. 85-98, Birkhauser, Boston, Mass, USA, 1998.

[56] R. R. Markwald, T. Nakaoka, and C. H. Mjaatvedt, "Overview: formation of the primary heart tube," in Etiology and Morphogenesis of Congenital Heart Disease: Twenty Years of Progress in Genetics and Developmental Biology, E. B. Clark, M. Nakazawa, and A. Takao, Eds., pp. 103-114, Futura, New York, NY, USA, 2000.

[57] K. Linask, Y. H. Gui, R. Rasheed, and L. Kwon, "Pattern development during pericardial coelom formation and specification of the cardiomyocyte cell population by N-cadherin and the Drosophila armadillo protein homologue in the early chick embryo," Molecular Biology of the Cell, vol. 3, p. 206A, 1992.

[58] C. L. Cai, X. Liang, Y. Shi et al., "Isl1 identifies a cardiac progenitor population that proliferates prior to differentiation and contributes a majority of cells to the heart," Developmental Cell, vol. 5, no. 6, pp. 877-889, 2003.

[59] M. P. Verzi, D. J. McCulley, S. De Val, E. Dodou, and B. L. Black, "The right ventricle, outflow tract, and ventricular septum comprise a restricted expression domain within the secondary/anterior heart field," Developmental Biology, vol. 287, no. 1, pp. 134-145, 2005.

[60] C. A. Loffredo, "Epidemiology of cardiovascular malformations: prevalence and risk factors," American Journal of Medical Genetics, vol. 97, pp. 319-325, 2000.

[61] M. L. Kirby, A. Lawson, H. A. Stadt et al., "Hensen's node gives rise to the ventral midline of the foregut: implications for organizing head and heart development," Developmental Biology, vol. 253, no. 2, pp. 175-188, 2003.

[62] E. M. Pera and E. M. De Robertis, "A direct screen for secreted proteins in Xenopus embryos identifies distinct activities for the Wnt antagonists crescent and frzb-1," Obstetrics and Gynecology, vol. 96, no. 3, pp. 183-195, 2000.

[63] A. F. Schier, S. C. F. Neuhauss, K. A. Helde, W. S. Talbot, and W. Driever, "The one-eyed pinhead gene functions in mesoderm and endoderm formation in zebrafish and interacts with no tail," Development, vol. 124, no. 2, pp. 327-342, 1997

[64] R. Seifert, M. Jacob, and H. J. Jacob, "The avian prechordal head region: a morphological study," Journal of Anatomy, vol. 183, part 1, pp. 75-89, 1993.

[65] A. Wessels, R. H. Anderson, R. R. Markwald et al., "Atrial development in the human heart: an immunohistochemical study with emphasis on the role of mesenchymal tissues," The Anatomical Record, vol. 259, pp. 288-300, 2000.

[66] R. H. Anderson, S. Webb, N. A. Brown, W. Lamers, and A. Moorman, "Development of the heart: (3) Formation of the ventricular outflow tracts, arterial valves, and intrapericardial arterial trunks," Heart, vol. 89, no. 9, pp. 1110-1118, 2003.

[67] B. S. Snarr, E. E. Wirrig, A. L. Phelps, T. C. Trusk, and A. Wessels, "A spatiotemporal evaluation of the contribution of the dorsal mesenchymal protrusion to cardiac development," Developmental Dynamics, vol. 236, no. 5, pp. 1287-1294, 2007

[68] J. Lincoln, A. W. Lange, and K. E. Yutzey, "Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development," Developmental Biology, vol. 294, no. 2, pp. 292-302, 2006.

[69] J. Lincoln and K. E. Yutzey, "Molecular and developmental mechanisms of congenital heart valve disease," Birth Defects Research A, vol. 91, no. 6, pp. 526-534, 2011.

[70] J. S. Fitzgerald, A. Germeyer, B. Huppertzet al., "Governing the invasive trophoblast: current aspects on intra- and extracellular regulation," American Journal of Reproductive Immunology, vol. 63, no. 6, pp. 492-505, 2010.

[71] L. Carrel, P. A. Hunt, and H. F. Willard, "Tissue and lineage-specific variation in inactive X chromosome expression of the murine Smcx gene," Human Molecular Genetics, vol. 5, no. 9, pp. 1361-1366, 1996.

[72] J. Cross, M. Hemberger, Y. Lu, T. Nozaki, and K. Whitely, "Trophoblast functins, angiogenesis and remodeling of the maternal vasculatrue in the placenta," Molecular and Cellular Endocrinology, vol. 187, pp. 207-212, 2002.

[73] N. J. Hannan and L. A. Salamonsen, "Role of chemokines in the endometrium and in embryo implantation," Current Opinion in Obstetrics and Gynecology, vol. 19, no. 3, pp. 266-272, 2007

[74] L. K. Harris, "Review: trophoblast-vascular cell Interactions in early pregnancy: how to remodel a vessel," Placenta, vol. 31, pp. S93-S98, 2010.

[75] S. Afonso, L. Romagnano, and B. Bablarz, "The expression and function of cystatin C and cathepsin B and cathepsin L during mouse embryo implantation and placentation," Development, vol. 124, no. 17, pp. 3415-3425, 1997

[76] A. Cattelino, S. Liebner, R. Gallini et al., "The conditional inactivation of the [beta]-catenin gene in endothelial cells causes a defective vascular pattern and increased vascular fragility," Journal of Cell Biology, vol. 162, no. 6, pp. 1111-1122, 2003.

[77] O. A. Mohamed, M. Jonnaert, C. Labelle-Dumais, K. Kuroda, H. J. Clarke, and D. Dufort, "Uterine Wnt/[beta]-catenin signaling is required for implantation," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 24, pp. 8579-8584, 2005.

[78] S. Caluwaerts, L. Vercruysse, C. Luyten, and R. Pijnenborg, "Endovascular trophoblast invasion and associated structural changes in uterine spiral arteries of the pregnant rat," Placenta, vol. 26, no. 7, pp. 574-584, 2005.

[79] M. A. Conti, S. Even-Ram, C. Liu, K. M. Yamada, and R. S. Adelstein, "Defects in cell adhesion and the visceral endoderm following ablation of nonmuscle myosin heavy chain II-A in mice," Journal of Biological Chemistry, vol. 279, no. 40, pp. 41263-41266, 2004.

[80] A. N. Tullio, D. Accili, V. J. Ferrans et al., "Nonmuscle myosin II-B is required for normal development of the mouse heart," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 23, pp. 12407-12412, 1997

[81] W. Lu, S. H. Seeholzer, M. Han et al., "Cellular nonmuscle myosins NMHC-IIA and NMHC-IIB and vertebrate heart looping," Developmental Dynamics, vol. 237, no. 12, pp. 3577-3590, 2008.

[82] S. Cains, A. Shepherd, M. Nabiuni, P. J. Owen-Lynch, and J. Miyan, "Addressing a folate imbalance in fetal cerebrospinal fluid can decrease the incidence of congenital hydrocephalus," Journal of Neuropathology and Experimental Neurology, vol. 68, no. 4, pp. 404-416, 2009.

[83] L. M. De-Regil, A. C. Fernandez-Gaxiola, T. Dowswell, and J. P. Pena-Rosas, "Effects and safety of periconceptional folate supplementation for preventing birth defects," Cochrane Database of Systematic Reviews, vol. 10, Article ID CD007950, 2010.

[84] A. Rosano, D. Smithells, L. Cacciani et al., "Time trends in neural tube defects prevalence in relation to preventive strategies: an international study," Journal of Epidemiology and Community Health, vol. 53, no. 10, pp. 630-635, 1999.

[85] S. Thompson, M. Torres, R. Stevenson, J. Dean, and R. Best, "Periconceptional vitamin use, dietary folate and occurrent neural tube defected pregnancies in a high risk population," Annals of Epidemiology, vol. 10, no. 7, p. 476, 2000.

[86] R. Ionescu-Ittu, A. J. Marelli, A. S. Mackie, and L. Pilote, "Prevalence of severe congenital heart disease after folic acid fortification of grain products: time trend analysis in Quebec, Canada," The British Medical Journal, vol. 338, p. b1673, 2009.

[87] A. Czeizel, "Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation," American Journal of Medical Genetics, vol. 62, pp. 179-183, 1996.

[88] A. E. Czeizel, E. H. Puho, Z. Langmar, N. Acs, and F. Banhidy, "Possible association of folic acid supplementation during pregnancy with reduction of preterm birth: a population-based study," European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 148, no. 2, pp. 135-140, 2010.

[89] L. Pickell, K. Brown, D. Li et al., "High intake of folic acid disrupts embryonic development in mice," Birth Defects Research A, vol. 91, no. 1, pp. 8-19, 2011.

[90] O. Aguilera, A. F. Fernandez, A. Munoz, and M. F. Fraga, "Epigenetics and environment: a complex relationship," Journal of Applied Physiology, vol. 109, no. 1, pp. 243-251, 2010.

[91] V. Bollati and A. Baccarelli, "Environmental epigenetics," Heredity, vol. 105, no. 1, pp. 105-112, 2010.

[92] L. M. Villeneuve and R. Natarajan, "The role of epigenetics in the pathology of diabetic complications," American Journal of Physiology, vol. 299, no. 1, pp. F14-F25, 2010.

[93] A. C. Foley and M. Mercola, "Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex," Genes and Development, vol. 19, no. 3, pp. 387-396, 2005.

[94] M. Broun, L. Gee, B. Reinhardt, and H. R. Bode, "Formation of the head organizer in hydra involves the canonical Wnt pathway," Development, vol. 132, no. 12, pp. 2907-2916, 2005.

[95] C. Carmona-Fontaine, H. K. Matthews, S. Kuriyama et al., "Contact inhibition of locomotion in vivo controls neural crest directional migration," Nature, vol. 456, no. 7224, pp. 957-961, 2008.

[96] M. A. Chacon, L. Varela-Nallar, and N. C. Inestrosa, "Frizzled-1 is involved in the neuroprotective effect of Wnt3a against A[beta] oligomers," Journal of Cellular Physiology, vol. 217, no. 1, pp. 215-227, 2008.

[97] T. M. Nafee, W. E. Farrell, W. D. Carroll, A. A. Fryer, and K. M. K. Ismail, "Epigenetic control of fetal gene expression," British Journal of Obstetrics and Gynaecology, vol. 115, no. 2, pp. 158-168, 2008.

[98] J. C. Kiefer, "Epigenetics in development," Developmental Dynamics, vol. 236, no. 4, pp. 1144-1156, 2007.

[99] S. Gessert and M. Kuhl, "The multiple phases and faces of Wnt signaling during cardiac differentiation and development," Circulation Research, vol. 107, no. 2, pp. 186-199, 2010.

[100] O. Aguilera, M. F. Fraga, E. Ballestar et al., "Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer," Oncogene, vol. 25, no. 29, pp. 4116-4121, 2006.

[101] Y. Liu, Y. Balaraman, G. Wang, K. P. Nephew, and F. C. Zhou, "Alcohol exposure alters DNA methylation profiles in mouse embryos at early neurulation," Epigenetics, vol. 4, no. 7, pp. 500-511, 2009.

[102] F. C. Zhou, Y. Chen, and A. Love, "Cellular DNA methylation program during neurulation and its alteration by alcohol exposure," Birth Defects Research A, vol. 91, no. 8, pp. 703-715, 2011.

[103] L. A. Ouko, K. Shantikumar, J. Knezovich, P. Haycock, D. J. Schnugh, and M. Ramsay, "Effect of alcohol consumption on CpG methylation in the differentially methylated regions of H19 and IG-DMR in male gametes--implications for fetal alcohol spectrum disorders," Alcoholism, vol. 33, no. 9, pp. 1615-1627, 2009.

[104] L. Burd, E. Deal, R. Rios, E. Adickes, J. Wynne, and M. G. Klug, "Congenital heart defects and fetal alcohol spectrum disorders," Congenital Heart Disease, vol. 2, no. 4, pp. 250-255, 2007

[105] P W. Yoon, R. S. Olney, M. J. Khoury, W. M. Sappenfield, G. F. Chavez, and D. Taylor, "Contribution of birth defects and genetic diseases to pediatric hospitalizations: a population-based study," Archives of Pediatrics and Adolescent Medicine, vol. 151, no. 11, pp. 1096-1103, 1997

[106] W. J. Larsen, Human Embryology, Churchill Livingstone, New York, NY, USA, 1993.

Kersti K. Linask

USF Children's Research Institute, CRI #2007, Department of Pediatrics, 140-7th Avenue South, St. Petersburg, FL 33701, USA

Correspondence should be addressed to Kersti K. Linask; klinask@health.usf.edu

Received 8 November 2012; Revised 4 March 2013; Accepted 13 March 2013

Academic Editor: Riitta Luoto
COPYRIGHT 2013 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Linask, Kersti K.
Publication:Journal of Pregnancy
Article Type:Report
Date:Jan 1, 2013
Words:7458
Previous Article:Effect of folic acid supplementation in pregnancy on preeclampsia: the folic acid clinical trial study.
Next Article:Current thoughts on maternal nutrition and fetal programming of the metabolic syndrome.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters